Physician profile
Srisha Rao
NPI 1578548970
$8,843.89
in general payments reported to CMS, 2019-2025
32 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $569 · 2021: $1,393 · 2022: $1,586 · 2023: $1,730 · 2024: $1,699 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,631.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,126.55 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $962.85 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $689.18 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $591.58 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $486.88 | 2021-2025 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.61 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $445.02 | 2020-2025 | Varithena Administration Pack, General - Therapies |
| Cvrx, INC. | $427.23 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $424.34 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $380.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $343.81 | 2022-2025 | Brilinta, Farxiga |
| Merck Sharp & Dohme LLC | $315.42 | 2021-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $256.46 | 2023-2024 | Inpefa |
| Stryker Corporation | $253.05 | 2021 | |
| Kestra Medical Technology Services, INC. | $243.35 | 2024-2025 | Assure Wcd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $237.97 | 2022-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $209.66 | 2019-2025 | Camzyos, Eliquis |
| Biotronik INC. | $184.58 | 2021 | |
| Abbott Laboratories | $174.87 | 2022-2024 | Mitraclip, Jot Dx |
| Sanofi-Aventis U.S. LLC | $95.08 | 2019-2023 | |
| Esperion Therapeutics, INC. | $88.34 | 2021-2024 | Nexletol |
| Atricure, INC. | $83.03 | 2023-2024 | |
| Astellas Pharma US INC | $81.55 | 2019-2020 | |
| Philips North America LLC | $64.10 | 2022-2025 | (Ck4) Mcot, Ecc Solutions |
| Medtronic, INC. | $56.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $47.31 | 2019-2024 | Dupixent |
| Novo Nordisk INC | $29.79 | 2021-2022 | |
| Edwards Lifesciences Corporation | $24.13 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.90 | 2022 | |
| Angiodynamics, INC. | $16.53 | 2021 | |
| Cleerly, INC. | $14.92 | 2023 | Cleerly Labs |
| Lundbeck LLC | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srisha Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.